Tumor Mutations and VTE Risk – New Insights from a 12,500-Patient Cancer Study – JTH
Journal of Thrombosis and Haemostasis (JTH) shared a post on LinkedIn about a recent article by Naomi Cornish et al, adding:
”Associations of Tumor Somatic Mutations with Cancer-Associated Venous Thromboembolism
Analysis of 12,507 cancer patients reveals that somatic mutations in CDKN2A, KRAS, PCDH15, and TP53 significantly increase VTE risk, while high tumor mutational burden is protective, offering novel insights into cancer-associated thrombosis pathophysiology and future risk prediction tools.”
Title: Associations of tumor somatic mutations with cancer-associated venous thromboembolism
Authors: Naomi Cornish, Rebecca Ward, Matthew T. Warkentin, Chrissie Thirlwell, Andrew D. Mumford, Sarah K. Westbury, Philip C. Haycock
Read the Full Article on JTH

Stay updated on all scientific advances with Hemostasis Today.
-
Oct 5, 2026, 15:31Irma Bagdoniene: Multidisciplinary Management of High-Risk Familial Hypercholesterolaemia and CAD
-
Oct 5, 2026, 15:00Serena Williams and Pulmonary Embolism: From Personal Crisis to Lessons in Venous Thromboembolism
-
Oct 5, 2026, 14:55Marco Moscarelli: 3D Reconstruction Enhances Volumetric Assessment of Post-TAVI Thrombosis
-
Oct 5, 2026, 13:24Abdul Muqtadir Abbasi: Diagnostic Pearls for Evaluating Isolated Thrombocytopenia in Residents
-
Oct 5, 2026, 13:16Katerina Pavenski: Rethinking What ‘Normal’ Means for Iron Deficiency
-
Oct 5, 2026, 13:09Rick Matthews: Balancing Established VTE Partnerships with Innovative Interventional Technologies
-
Oct 5, 2026, 13:01Nawsherwan Mohammad: Recognizing TTP Before the ADAMTS13 Result Arrives
-
Oct 5, 2026, 12:51Bruno Pougault: The Hidden Challenges Behind Anti Xa Testing
-
Oct 5, 2026, 12:41Syed Huzaifa Khan: Rethinking CTRP12 as a Biomarker for In Stent Restenosis